- Home
- TNGX vs KMDA Comparison
TNGX vs KMDA Comparison
Compare TNGX & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- KMDA
- Stock Information
- Founded
- TNGX 2014
- KMDA 1990
- Country
- TNGX United States
- KMDA Israel
- Employees
- TNGX N/A
- KMDA N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- TNGX Health Care
- KMDA Health Care
- Exchange
- TNGX Nasdaq
- KMDA Nasdaq
- Market Cap
- TNGX 317.4M
- KMDA 349.1M
- IPO Year
- TNGX N/A
- KMDA N/A
- Fundamental
- Price
- TNGX $1.29
- KMDA $6.50
- Analyst Decision
- TNGX Strong Buy
- KMDA Strong Buy
- Analyst Count
- TNGX 7
- KMDA 3
- Target Price
- TNGX $12.33
- KMDA $14.67
- AVG Volume (30 Days)
- TNGX 756.3K
- KMDA 119.9K
- Earning Date
- TNGX 05-07-2025
- KMDA 05-07-2025
- Dividend Yield
- TNGX N/A
- KMDA 3.06%
- EPS Growth
- TNGX N/A
- KMDA 66.67
- EPS
- TNGX N/A
- KMDA 0.25
- Revenue
- TNGX $42,069,000.00
- KMDA $160,953,000.00
- Revenue This Year
- TNGX N/A
- KMDA $14.01
- Revenue Next Year
- TNGX N/A
- KMDA $9.24
- P/E Ratio
- TNGX N/A
- KMDA $26.51
- Revenue Growth
- TNGX 15.17
- KMDA 12.93
- 52 Week Low
- TNGX $1.11
- KMDA $4.74
- 52 Week High
- TNGX $12.02
- KMDA $9.15
- Technical
- Relative Strength Index (RSI)
- TNGX 37.63
- KMDA 50.01
- Support Level
- TNGX $1.25
- KMDA $5.78
- Resistance Level
- TNGX $1.44
- KMDA $6.21
- Average True Range (ATR)
- TNGX 0.15
- KMDA 0.30
- MACD
- TNGX 0.03
- KMDA 0.04
- Stochastic Oscillator
- TNGX 45.00
- KMDA 75.59
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.